TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation’s common shares trade on the OTCQB Market under the symbol ‘TEAR’.
Company profile
Ticker
TEAR
Exchange
Website
CEO
Joseph S. Jensen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OccuLogix, Inc.
SEC CIK
Corporate docs
IRS number
593434771
TEAR stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 20
Latest ownership filings
4
ELIAS VAMVAKAS
10 Jul 20
4
Michael Marquez
9 Jul 20
4
Richard Lindstrom
9 Jul 20
4
Paul Karpecki
9 Jul 20
4
Joseph Jensen
9 Jul 20
4
ANTHONY E ALTIG
9 Jul 20
3
Initial statement of insider ownership
6 Jul 20
SC 13D/A
CR Group L.P.
9 Jun 20
SC 13D
CR Group L.P.
21 May 20
4
RICHARD L MD LINDSTROM
12 Mar 20
Financial summary
Quarter (USD) | Mar 20 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|